---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-25-000165"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:27.226045+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M

## Summary
- GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).
- Consumable revenue record $21.3M (+15% YoY); instrument revenue $11.3M (down 33% YoY).
- Non-GAAP gross margin improved to 42% from 33% YoY; operating expenses cut to $53.9M from $62.4M.
- Revio systems shipped 13 (vs 22); Vega systems shipped 32; cash and investments $298.7M.
- Launched SPRQ-Nx chemistry to reduce sequencing costs up to 40%; Sequel II CNDx approved in China.

## SEC filing metadata
- accession: 0001299130-25-000165
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/0001299130-25-000165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913025000165/pacb-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-25-000165
- JSON: https://secwatch.observer/filing/0001299130-25-000165.json
- Plain text: https://secwatch.observer/filing/0001299130-25-000165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.